MBX Biosciences is a preclinical-stage biotech company committed to creating therapies to treat rare endocrine diseases where there is inadequate treatment available.

MBX’s leadership team has collaborated successfully over several decades to discover, develop and commercialize first-in-class endocrine therapeutics. A distinguishing strength of MBX is world-class proprietary peptide drug discovery.

Management Team

Kent Hawryluk, MS, MBAPresident & CEO

Kent Hawryluk has nearly 20 years’ experience as a life sciences entrepreneur, leader and investor. Mr. Hawryluk is President & CEO and one of our co-founders.

Mr. Hawryluk was a Co-founder and Chief Business Officer of Avidity Biosciences, a genetic medicines company, from January 2013 to December 2019. Under his leadership, Avidity raised $130 million in equity financings and initiated a significant strategic partnership with Eli Lilly. Previously, he served as Co-founder and CEO of MB2, a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Prior to MB2 and Avidity, Mr. Hawryluk co-founded Marcadia Biotech and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia, a pioneer in peptide multi-agonists of incretin receptors, was acquired by Roche in December 2010. Mr. Hawryluk served as a director of Gemphire Therapeutics, a public clinical-stage cardiovascular drug company, from February 2015 to February 2019. He has served as partner of Twilight Venture Partners, a private seed- and early-stage life science venture capital fund, since January 2003. Mr. Hawryluk holds a BA from Princeton University, an MBA from Kellogg School of Management at Northwestern University, and an MS, Biology from Purdue University.

Tim KnickerbockerChief Operating Officer

Timothy Knickerbocker is an Indiana native and Purdue University alumnus, seasoned by professional employment in the Midwest and California. He has served in leadership roles in project management and operations pertaining to the life sciences. Mr. Knickerbocker is COO and one of our co-founders.

Prior to his time at MBX, Mr. Knickerbocker successfully led teams in the building of some of the most technically advanced healthcare facilities in the country. He is currently complementing his operational duties at MBX with an Executive MBA education from the Anderson School of Management at UCLA.

Richard DiMarchi, PhDChief Scientific Officer

Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University, where he served as chairman of the Chemistry Department. Dr. DiMarchi is a member of the National Academy of Medicine and the National Inventors Hall of Fame. He is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity. He is chairman of the Peptide Therapeutics Foundation and is widely recognized as an international spokesperson for macromolecular medicines.

Dr. DiMarchi is co-inventor on more than 100 U.S. patents and co-author to more than 250 peer-reviewed scientific publications. He was identified as a top-five translation researcher by Nature Biotechnology for the years 2014 and 2015. MBX is the sixth biotech company he has co-founded following successes with Ambrx, Marcadia, Calibrium, MB2 and Assembly. In the last decade Dr. DiMarchi has received the 2011 Merrifield Award for career contributions in peptide sciences, the 2014 German National Erwin Schrödinger-Preis, the 2015 Meienhofer Prize, the 2015 Max Bergmann Medal, and the 2016 ACS Alfred Burger career award in medicinal chemistry.

Mary Jane Geiger, MD, PhDChief Medical Officer

Mary Jane Geiger, MD, PhD has 20 years of biopharmaceutical industry experience and has led all phases of clinical development. She serves as our Chief Medical Officer.

Dr. Geiger previously served as vice president, drug development services – cardiovascular, at ICON, a global clinical research organization. She provided cardio-metabolic and renal therapeutic area and rare disease consulting and drug development expertise to pharmaceutical and biotech clients, assisting them in the successful development and delivery of their drug development portfolio. She previously served as senior director, cardiovascular and metabolism at Regeneron Pharmaceuticals, a publicly-traded biopharmaceutical company; as vice president, clinical development at Relypsa, a private pharmaceutical company; and as medical fellow I, Lilly Diabetes at Eli Lilly and Company. During her tenure at Lilly, Dr. Geiger was responsible for clinical development of Trulicity® from post-Phase 1 through completion of pivotal clinical studies. She began her biopharmaceutical industry career at Merck in 2000, and before this was in private practice, a clinical trial investigator, IRB member and chairman of the department of internal medicine. Dr. Geiger earned her bachelor’s degree in biology from Marquette University, and her medical doctorate and Ph.D. from the Medical College of Wisconsin in Milwaukee, Wisconsin. She completed her internal medicine internship and residency at Duke University Medical Center with additional research in nephrology and cardiology, and has authored numerous scientific and clinical publications.

Lisa Redman, CPAVice President, Finance

Lisa J. Redman has more than 25 years of finance and accounting experience. Ms. Redman is our Vice President, Finance. 

Previously, Ms. Redman was head of finance for MB2 during its purchase of Marcadia Biotech and its acquisition by Novo Nordisk. She has served in key finance roles in numerous biotechnology companies including Crinetics Pharmaceuticals and Auspex Pharmaceuticals where she was integrally involved with their IPO preparations. Further, Ms. Redman also helped companies with SEC reporting, Sarbanes-Oxley implementations and grant compliances.

Ms. Redman was a CFO of a publicly held technology company and a controller of several venture-backed companies in a variety of industries including medical devices, food distribution and mortgage banking. She began her career as an auditor for Coopers & Lybrand (now PWC) where she served both public and private companies. Ms. Redman holds a bachelor’s degree in Business Administration from San Diego State University. She is a Certified Public Accountant in the State of California (on inactive status).

Greg Davis, PhDVice President, Product Development

Greg Davis, PhD, has nearly 35 years’ experience in drug development in biotech and pharma. Dr. Davis is our Vice President, Product Development.

Dr. Davis has served as Chairman of the Board of Inotiv, a publicly-traded clinical research organization, since June 2017. He served as Vice President of CMC, Regulatory and Quality at Calibrium, a biotech company developing novel biotherapeutics for the treatment of diabetes, from May 2014 to December 2015. The company was sold to Novo Nordisk in October 2015. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly in Biotechnology Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. When he retired from Eli Lilly in December of 2012, he was Executive Director and Senior Principal Fellow in Global Regulatory Affairs. Dr. Davis has held numerous leadership positions within the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States Pharmacopeia (USP), and the Biotechnology Industry Organization (BIO). He also served for five years as the PhRMA liaison to the International Conference on Harmonization (ICH) for Q5/Q6 Biotechnology topics. Dr. Davis received his bachelor’s degree from Southeast Missouri State University and his PhD in Analytical Chemistry from Purdue University.

Michael A. Dorato, PhD, DABT, Fellow ATSVice President Pharmacology and Toxicology

Dr. Dorato has over 45 years of experience in pharmacology, toxicology and drug development. He has spent 30 years at Eli Lilly and Co, retiring as Executive Director, Toxicology and Greenfield Laboratories Site Head. Dr. Dorato also has significant experience in the Toxicology CRO industry, spending 5 years at Covance as Vice President and CSO Global Discovery Services; 5 years at Smithers Avanza as Executive Vice President Toxicology Services; 2 Years at Inotiv, as Sr. Vice President Toxicology and Pharmacology. In these positions he has led global organizations in safety and efficacy, lead optimization, investigative and regulatory toxicology, discovery and late phase pathology, animal welfare, molecular and anatomical imaging, in vivo pharmacology (oncology, neuroscience, cardiovascular and metabolic disease, inflammation, renal, bone, receptor occupancy), developmental and reproductive toxicology, and model development. Dr. Dorato has led drug development decisions in various phases of pharmaceutical research and development, organizational growth initiatives, and development of leaders. He is a Fellow of the Academy of Toxicological Sciences, a Diplomate of the American Board of Toxicology, an Emeritus member of the Society of Toxicology and a full member of the American College of Toxicology.

Skip Vignati, MD, MSSenior Medical Consultant

Dr. Louis “Skip” Vignati, Senior Medical Consultant, is a board-certified endocrinologist with broad clinical and drug discovery experience spanning 40 years. Dr. Vignati served as Vice President, Medical Affairs at Calibrium, a biotech company developing novel biotherapeutics for the treatment of diabetes, from June 2014 until Calibrium was acquired by Novo Nordisk in December 2015. Previously, he was Vice President, Medical at Marcadia Biotech, a pioneer in peptide multi-agonists of incretin receptors, from September 2006 to April 2011. Marcadia was acquired by Roche in December 2010.

He received an undergraduate degree from the University of Pennsylvania, a graduate degree in organic chemistry from American University and a medical degree from Thomas Jefferson University. He completed his house staff training at the University of Vermont and Endocrine Fellowship at the Peter Bent Brigham Hospital and the Elliot P. Joslin Research Laboratory in Boston, Massachusetts. He served as an officer in the USPHS in the Toxicology Branch of the National Institute of Health for Occupational Safety and Health.

Following his fellowship, Dr. Vignati was senior physician at the Joslin Diabetes Center in Boston, Massachusetts. In 1990 he joined Eli Lilly and Company and served as the Medical Director for development of early phase endocrine compounds. At Lilly he participated in the global development of new therapies for the treatment of diabetes and its complications and obesity including Humalog®, Recombinant Glucagon®, and Forteo® among others. Dr. Vignati has been a principal investigator for numerous clinical trials and co-investigator for the DCCT (Diabetes Control and Complications Trial).

Kristin EatonSenior Intellectual Property Consultant

Kristin Eaton has 24 years’ cumulative experience in scientific research and intellectual property development.

Upon graduating from the University of Chicago with a BA in biology, Kristin conducted research at the University of Chicago Hospital’s Department of Neurology. Following this she worked in stem cell transplantation research at the University of Minnesota prior to and throughout the establishment of the UMN Stem Cell Institute. King & Spalding’s biotechnology IP group recruited Kristin for her unique skill set and while employed in their Atlanta office she passed the patent bar and spent years learning the details of patent prosecution, licensing, and investor due diligence before bringing those skills to bear in a stem cell focused biotechnology company in Massachusetts. Kristin moved to California where she has served as in-house IP director and strategist for a number of biotechnology companies in San Diego including Ambrx and Vividion. She works to combine her experiences with cutting-edge science and its interplay with politics and policy to pursue broad and innovative patent protection.


Board of Directors

Kent Hawryluk President & CEO, Director of MBX Biosciences

Kent Hawryluk has nearly 20 years’ experience as a life sciences entrepreneur, leader and investor. Mr. Hawryluk is President & CEO and one of our co-founders.

Mr. Hawryluk was a Co-founder and Chief Business Officer of Avidity Biosciences, a genetic medicines company, from January 2013 to December 2019. Under his leadership, Avidity raised $130 million in equity financings and initiated a significant strategic partnership with Eli Lilly. Previously, he served as Co-founder and CEO of MB2, a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Prior to MB2 and Avidity, Mr. Hawryluk co-founded Marcadia Biotech and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia, a pioneer in peptide multi-agonists of incretin receptors, was acquired by Roche in December 2010. Mr. Hawryluk served as a director of Gemphire Therapeutics, a public clinical-stage cardiovascular drug company, from February 2015 to February 2019. He has served as partner of Twilight Venture Partners, a private seed- and early-stage life science venture capital fund, since January 2003. Mr. Hawryluk holds a BA from Princeton University, an MBA from Kellogg School of Management at Northwestern University, and an MS, Biology from Purdue University.

Richard DiMarchiCSO of MBX Biosciences

Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University, where he served as chairman of the Chemistry Department. Dr. DiMarchi is a member of the National Academy of Medicine and the National Inventors Hall of Fame. He is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon physiology and the discovery of single molecule multimode agonists for the treatment of diabetes and obesity. He is chairman of the Peptide Therapeutics Foundation and is widely recognized as an international spokesperson for macromolecular medicines.

Dr. DiMarchi is co-inventor on more than 100 U.S. patents and co-author to more than 250 peer-reviewed scientific publications. He was identified as a top-five translation researcher by Nature Biotechnology for the years 2014 and 2015. MBX is the sixth biotech company he has co-founded following successes with Ambrx, Marcadia, Calibrium, MB2 and Assembly. In the last decade Dr. DiMarchi has received the 2011 Merrifield Award for career contributions in peptide sciences, the 2014 German National Erwin Schrödinger-Preis, the 2015 Meienhofer Prize, the 2015 Max Bergmann Medal, and the 2016 ACS Alfred Burger career award in medicinal chemistry.

Patrick HeronManaging Partner of Frazier Healthcare Partners

Patrick Heron is a Managing Partner of Frazier’s Life Sciences team. He joined the firm in 1999 and opened Frazier’s Menlo Park office in 2003. Throughout his 15 years as a Managing Partner, Mr. Heron has led or co-led investments across 30 companies. He has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage drug discovery companies to >$100M commercial-stage dermatology companies. Mr. Heron currently serves on the boards of Arcutis (NASDAQ: ARQT), Imago BioSciences, Iterum Therapeutics (NASDAQ: ITRM), Mirum Pharmaceuticals (NASDAQ: MIRM), MBX Biosciences, Passage Bio (NASDAQ: PASG), ScoutBio, and SutroVax (NASDAQ:PCVX). He received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.

Ed MathersGeneral Partner of New Enterprise Associate

Ed Mathers is a General Partner at NEA; he joined the firm as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Rhythm Pharmaceuticals (NASDAQ: RYTM), Synlogic (NASDAQ:SYBX), Trevi Therapeutics (NASDAQ: TRVI), Mirum Pharmaceuticals (NASDAQ:MIRM), and ObsEva (NASDAQ:OBSV), as well as a number of private life sciences companies. Prior to joining NEA, Mr. Mathers served as executive vice president, corporate development and venture at MedImmune, a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures. Prior to this, he spent 15 years at Glaxo Wellcome (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. Mr. Mathers earned his bachelor’s degree in chemistry from North Carolina State University.

Carl GordonManaging Partner of OrbiMed

Carl L. Gordon, CFA, Ph.D is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. Dr. Gordon serves on the boards of several public and private companies. Additionally, Dr. Gordon was a Fellow at The Rockefeller University. Dr. Gordon received a B.A. in Chemistry from Harvard College and a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology.

Jim CorneliusRetired Chairman & CEO, Bristol Myers Squibb

Jim Cornelius is an accomplished global biopharmaceutical leader, with past board and leadership roles at Bristol Myers Squibb and Eli Lilly, as well as a recognized venture investor and philanthropist.

Mr. Cornelius served as Chairman of the Board of Mead Johnson Nutrition (MJN) from December 2009 to June 2017, when MJN was acquired by Reckitt Benckiser for $16 billion.  Previously, he served as Chairman of the Board of Bristol Myers Squibb (BMY) from February 2008 to May 2015, and also held the title Chief Executive Officer from September 2006 to March 2010. BMY completed a successful transformation into a leading specialty biopharmaceutical enterprise during that time. 

Mr. Cornelius served as Board Chairman and Chief Executive Officer of Guidant (GDT) from November 2005 to April 2006, when it was acquired by Boston Scientific (BSX) for $27 billion. Previously, he was executive Chairman of the Board of Guidant and its senior executive starting from September 1994   when the Company was formed within Eli Lilly (LLY). Mr. Cornelius was a member of LLY’s Board of Directors and its Chief Financial Officer from 1983 until 1995. 

In addition, he has served on the Board of Directors of a dozen private and public companies, including The Chubb Corporation, The DIRECTV Group and Given Imaging. Mr. Cornelius is currently Chairman of Cornelius Family Foundation and Cornelius Private Investments. He earned a B.A. magna cum laude and M.B.A. from Michigan State University.


Investors